Wendy Goodspeed

2.3k total citations
22 papers, 567 citations indexed

About

Wendy Goodspeed is a scholar working on Oncology, Genetics and Neurology. According to data from OpenAlex, Wendy Goodspeed has authored 22 papers receiving a total of 567 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Genetics and 7 papers in Neurology. Recurrent topics in Wendy Goodspeed's work include Cancer Treatment and Pharmacology (7 papers), Otitis Media and Relapsing Polychondritis (7 papers) and Neuroblastoma Research and Treatments (6 papers). Wendy Goodspeed is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Otitis Media and Relapsing Polychondritis (7 papers) and Neuroblastoma Research and Treatments (6 papers). Wendy Goodspeed collaborates with scholars based in United States, United Kingdom and France. Wendy Goodspeed's co-authors include Frank M. Balis, Brigitte C. Widemann, Elizabeth Fox, Anne Goodwin, Peter C. Adamson, Susan M. Blaney, Eva Dombi, John M. Maris, M O'Brien and Andrew Krivoshik and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

Wendy Goodspeed

21 papers receiving 565 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wendy Goodspeed United States	12	226	172	162	129	70	22	567
Carmen Julia Tartari Italy	11	227 1.0×	63 0.4×	97 0.6×	108 0.8×	33 0.5×	25	421
Ramamoorthy Nagasubramanian United States	11	357 1.6×	191 1.1×	437 2.7×	365 2.8×	83 1.2×	31	1.1k
Bernard Lemieux Canada	15	195 0.9×	221 1.3×	96 0.6×	255 2.0×	31 0.4×	36	796
Pablo Berlanga France	12	186 0.8×	140 0.8×	167 1.0×	181 1.4×	55 0.8×	54	492
Markus Cybulla Germany	16	214 0.9×	73 0.4×	85 0.5×	215 1.7×	106 1.5×	31	949
Alicia Morresi‐Hauf Germany	16	214 0.9×	208 1.2×	233 1.4×	266 2.1×	12 0.2×	42	792
Sevil Kılçıksız Türkiye	10	105 0.5×	45 0.3×	65 0.4×	125 1.0×	33 0.5×	27	377
Michele Fernandes United States	5	144 0.6×	52 0.3×	209 1.3×	143 1.1×	19 0.3×	5	383
Bobin Chen China	12	104 0.5×	239 1.4×	43 0.3×	125 1.0×	13 0.2×	66	501
Merry Tetef United States	14	147 0.7×	67 0.4×	119 0.7×	269 2.1×	7 0.1×	29	581

Countries citing papers authored by Wendy Goodspeed

Since Specialization

Citations

This map shows the geographic impact of Wendy Goodspeed's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wendy Goodspeed with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wendy Goodspeed more than expected).

Fields of papers citing papers by Wendy Goodspeed

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wendy Goodspeed. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wendy Goodspeed. The network helps show where Wendy Goodspeed may publish in the future.

Co-authorship network of co-authors of Wendy Goodspeed

This figure shows the co-authorship network connecting the top 25 collaborators of Wendy Goodspeed. A scholar is included among the top collaborators of Wendy Goodspeed based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wendy Goodspeed. Wendy Goodspeed is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Patel, Bhavisha A., Emma M. Groarke, Ruba Shalhoub, et al.. (2024). Patient Reported Outcomes in Vexas Syndrome. Blood. 144(Supplement 1). 3711–3711.

Patel, Bhavisha A., Marcela A. Ferrada, Kaitlin A. Quinn, et al.. (2023). Clinical Manifestations Are Evolving and Progressive in Patients with Vexas Syndrome. Blood. 142(Supplement 1). 703–703. 1 indexed citations

Rose, Emily, Marcela A. Ferrada, Kaitlin A. Quinn, et al.. (2021). Physician Global Assessment as a Disease Activity Measure for Relapsing Polychondritis. Arthritis Care & Research. 74(8). 1269–1276. 5 indexed citations

Luo, Yiming, Kaitlin A. Quinn, Kristina V Wells, et al.. (2021). A prospective observational cohort study and systematic review of 40 patients with mouth and genital ulcers with inflamed cartilage (MAGIC) syndrome. Seminars in Arthritis and Rheumatism. 52. 151924–151924. 5 indexed citations

Rimland, Casey A., Kaitlin A. Quinn, Marcela A. Ferrada, et al.. (2020). Utility of the Brief Illness Perception Questionnaire to Monitor Patient Beliefs in Systemic Vasculitis. The Journal of Rheumatology. 47(12). 1785–1792. 11 indexed citations

Ferrada, Marcela A., Casey A. Rimland, Kaitlin A. Quinn, et al.. (2020). Defining Clinical Subgroups in Relapsing Polychondritis: A Prospective Observational Cohort Study. Arthritis & Rheumatology. 72(8). 1396–1402. 23 indexed citations

Akshintala, Srivandana, Leigh Marcus, Katherine E. Warren, et al.. (2015). Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors. Pediatric Blood & Cancer. 62(4). 603–610. 15 indexed citations

Widemann, Brigitte C., Dusica Babovic‐Vuksanovic, Eva Dombi, et al.. (2014). Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Pediatric Blood & Cancer. 61(9). 1598–1602. 64 indexed citations

Widemann, Brigitte C., R.J. Arceci, Nalini Jayaprakash, et al.. (2010). Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: A report from the Children's Oncology Group. Pediatric Blood & Cancer. 56(2). 226–233. 21 indexed citations

10.

Fox, Elizabeth, Richard Aplenc, Rochelle Bagatell, et al.. (2010). A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors. Journal of Clinical Oncology. 28(35). 5174–5181. 94 indexed citations

11.

Jacobs, Shana, Elizabeth Fox, Mark Krailo, et al.. (2010). Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group. Clinical Cancer Research. 16(2). 750–754. 35 indexed citations

12.

Fox, Elizabeth, John M. Maris, Susan L. Cohn, et al.. (2009). Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. Cancer Chemotherapy and Pharmacology. 66(4). 737–743. 15 indexed citations

13.

Gillespie, Andrea, Eva Dombi, Anne Goodwin, et al.. (2009). Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas. Neurology. 73(16). 1273–1279. 59 indexed citations

14.

Fox, Elizabeth, John M. Maris, Brigitte C. Widemann, et al.. (2008). A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors. Clinical Cancer Research. 14(4). 1111–1115. 41 indexed citations

15.

Cole, Diane E., Frank M. Balis, Nicole Grant, et al.. (2008). Pharmacokinetics (pk) and tolerance of infusional vincristine (vcr) for aggressive lymphomas indicate dose reductions for excretory organ dysfunction are not necessary. Journal of Clinical Oncology. 26(15_suppl). 2550–2550. 1 indexed citations

16.

Widemann, Brigitte C., Wendy Goodspeed, Anne Goodwin, et al.. (2008). Phase I Trial and Pharmacokinetic Study of Ixabepilone Administered Daily for 5 Days in Children and Adolescents With Refractory Solid Tumors. Journal of Clinical Oncology. 27(4). 550–556. 22 indexed citations

17.

Fox, Elizabeth, Bassem I. Razzouk, Brigitte C. Widemann, et al.. (2007). Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood. 111(2). 566–573. 91 indexed citations

18.

Fox, Elizabeth, John M. Maris, Brigitte C. Widemann, et al.. (2006). A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors. Clinical Cancer Research. 12(16). 4882–4887. 54 indexed citations

19.

Fox, Edward, Wendy Goodspeed, Anne Goodwin, et al.. (2005). Phase I trial of the epothilone B analog BMS-247550 (ixabepilone) in children with refractory solid tumors. Journal of Clinical Oncology. 23(16_suppl). 8529–8529. 5 indexed citations

20.

Cole, Diane E., Frank M. Balis, Elizabeth Lowe, et al.. (2005). Pharmacokinetics (pk) and tolerance of doxorubicin (dox) and etoposide (etop) during treatment of aggressive B-cell lymphomas indicate doses need not be routinely reduced for hepatic dysfunction. Journal of Clinical Oncology. 23(16_suppl). 6573–6573. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact